循证医学依据

 

 

1. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.

2. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals theirheterologous nature.

3. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenictrioxide in relapsed small cell lung cancer.

4. Successful establishment of patient-derived tumor xenografts from gastrointestinal stromal tumor-asingle center experience.

5. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

6. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.

7. Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a ZebrafishModel.

8. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.

9. Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.

10. Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review.

11. Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts.

12. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 inhepatocellular carcinoma: From patients to patient-derived tumor xenograft models.

13. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

14. Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis.

15. Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models ofGlioblastoma.

16. Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRASmutation.

17. Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor andstromal specific biomarkers.

18. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.

19. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer.

20. Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer.

21. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.

22. Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer.

23. Gene mutations in primary tumors and corresponding patientderived xenografts derived from non-small cell lung cancer.

24. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.

25. Initiation and Characterization of Small Cell Lung Cancer Patient-Derived Xenografts from Ultrasound-Guided Transbronchial Needle Aspirates.

26. Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer Patients.

27. One mouse, one patient paradigm: New avatars of personalized cancer therapy.

28. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.

29. Mouse hospital and co-clinical trial project—from bench to bedside.

30. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.

31. The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men.

32. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice.

33. Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies.

34. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.

35. Patient Derived Xenograft Models: An Emerging Platform for Translational Cancer Research.

36. Integrated Analysis of Transcriptome in Cancer Patient-Derived Xenografts.

37. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.

38. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.

39. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells.

40. Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer.

41. Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer.

42. Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

43. Establishment of genetically diverse patient-derived xenografts of colorectal cancer.

44. Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft.

45. Patient-derived xenograft models of breast cancer and their predictive power.

46. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.

 

如有全文需求,请联系我们